PURPOSE
Lung adenocarcinomas (LUADs) harboring concurrent mutations in KRAS and STK11 define a clinically aggressive subgroup characterized by primary resistance to immune checkpoint inhibitors (ICIs). In contrast, KRAS/TP53 co-mutant tumors typically exhibit an inflamed tumor microenvironment (TME) and improved respon...
Carlos E. de Andrea, D. Ajona, C. Sainz et al.· Clinical Cancer Research· 0 citations
The evidence of clinical efficacy in a pretreated population, favorable tolerability and low rate of treatment discontinuation observed in Parts A and B support further evaluation of rilvegostomig in Parts C-E of the study, which assess safety and efficacy in CPI-naïve patients with nonsquamous and/or squamous NSCLC.
K. Rohrberg, M. Brandão, Eduardo Castañón Álvarez et al.· Clinical Cancer Research· 1 citation
Final analyses from this phase 2 study further supported substantial activity and prolonged OS with lorlatinib in treatment-naive and previously treated patients with ALK-positive advanced NSCLC, regardless of the biomarker subgroups.
T. Bauer, J. Martini, B. Besse et al.· Journal of Thoracic Oncology· 0 citations
In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.
A. Prelaj, V. Mišković, Matteo Sacco et al.· Nature Medicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.